Original article The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis

Paper

Original article The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis

Published 2011 · G. Torkildsen, A. Shedden

UNKNOWN SJR score

32

Citations

1

Influential Citations

Semantic Scholar

Abstract

Objective: The purpose of this study was to evaluate the safety and clinical efficacy of alcaftadine 0.25% ophthalmic solution, a new topical anti-allergic agent for the prevention of the signs and symptoms of allergic conjunctivitis induced by conjunctival allergen challenge (CAC). Study design and methods:

Non-RCT

Study Snapshot

Alcaftadine 0.25% ophthalmic solution is a safe and effective topical anti-allergenic agent for preventing itching associated with allergic conjunctivitis induced by conjunctival allergen challenge.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Original article The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis

Sign up to use Study Snapshot

References

Citations

A Randomized, Multicenter Phase 3 Clinical Trial Evaluating Intracanalicular Dexamethasone Insert for the Treatment of Allergic Conjunctivitis

Dexamethasone intracanalicular insert significantly improves ocular itching and conjunctival redness compared to placebo, with a generally safe and favorable safety profile.

Alcaftadine 0.25% Vs Olapatadine 0.2% Ophthalmic Solutions in Allergic Conjunctivitis: A Study in a Clinical Setting in South India

Alcaftadine 0.25% ophthalmic solution is more effective than Olapatadine 0.2% in treating allergic conjunctivitis symptoms, with both being safe and effective.

Stability-indicating UPLC, TLC-densitometric and UV-spectrophotometric methods for alcaftadine determination.

The developed stability-indicating methods effectively determine alcaftadine in ophthalmic solution and plasma samples, with accuracy comparable to previously reported methods.

Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report

Alcaftadine 0.25% may cause allergic contact dermatitis in both eyes, with swelling and erythematous changes resolved after 9 days of treatment.

Immunopathology of Allergic Conjunctivitis

Allergic conjunctivitis is primarily an immunoglobulin E-mediated hypersensitivity reaction to environmental allergens, with cellular and soluble mediators playing a major role in the pathophysiology and clinical manifestations.